denosumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hand Osteoarthritis
Conditions
Hand Osteoarthritis
Trial Timeline
Mar 1, 2016 → Apr 28, 2021
NCT ID
NCT02771860About denosumab + Placebo
denosumab + Placebo is a phase 2 stage product being developed by Amgen for Hand Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02771860. Target conditions include Hand Osteoarthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02771860 | Phase 2 | Completed |
| NCT00925600 | Phase 3 | Completed |
| NCT00890981 | Phase 3 | Completed |
| NCT00286091 | Phase 3 | Completed |
Competing Products
17 competing products in Hand Osteoarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lebrikizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Methylprednisolone Tablet | Johnson & Johnson | Phase 2/3 | 65 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Pimecrolimus Cream 1% | Novartis | Phase 3 | 77 |
| tocilizumab + saline solution | Roche | Phase 3 | 77 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |
| dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| clobetasol propionate | GSK plc | Approved | 84 |
| urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream) | Bayer | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 2 | 49 |
| Ruxolitinib | Incyte | Phase 1/2 | 38 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream | Arcutis Biotherapeutics | Phase 1/2 | 36 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |